| 000 | 01799 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250511180346.0 | ||
| 264 | 0 | _c19921020 | |
| 008 | 199210s 0 0 eng d | ||
| 022 | _a1043-0342 | ||
| 024 | 7 |
_a10.1089/hum.1992.3.4-411 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 245 | 0 | 0 |
_aThe treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombinant interleukin-2 alone, or with recombinant interleukin-2 and recombinant alpha interferon. _h[electronic resource] |
| 260 |
_bHuman gene therapy _cAug 1992 |
||
| 300 |
_a411-30 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aCD4 Antigens |
| 650 | 0 | 4 | _aCD8 Antigens |
| 650 | 0 | 4 | _aClinical Protocols |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aGenetic Engineering |
| 650 | 0 | 4 | _aGenetic Therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy, Adoptive |
| 650 | 0 | 4 |
_aInterferon Type I _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 | _aKanamycin Kinase |
| 650 | 0 | 4 |
_aKidney Neoplasms _xtherapy |
| 650 | 0 | 4 | _aLeukocyte Transfusion |
| 650 | 0 | 4 |
_aLeukocytes _ximmunology |
| 650 | 0 | 4 |
_aLymphocytes, Tumor-Infiltrating _ximmunology |
| 650 | 0 | 4 |
_aMelanoma _xsecondary |
| 650 | 0 | 4 |
_aPhosphotransferases _xgenetics |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 773 | 0 |
_tHuman gene therapy _gvol. 3 _gno. 4 _gp. 411-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/hum.1992.3.4-411 _zAvailable from publisher's website |
| 999 |
_c1332859 _d1332859 |
||